Active Ingredient History
Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Neuromyelitis Optica (approved 2020)
Autoimmune Diseases (Phase 2/Phase 3)
Encephalitis (Phase 2/Phase 3)
Immunoglobulin G4-Related Disease (Phase 3)
Kidney Transplantation (Phase 2)
Leukemia, B-Cell (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Lymphoma, B-Cell (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Multiple Myeloma (Phase 2)
Multiple Sclerosis (Phase 1)
Myasthenia Gravis (Phase 3)
Neoplasms (Phase 1)
Neuromyelitis Optica (Phase 2/Phase 3)
Psoriasis (Phase 3)
Scleroderma, Systemic (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
